GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harvard Apparatus Regenerative Technology Inc (OTCPK:HRGN) » Definitions » Intrinsic Value: Projected FCF

Harvard Apparatus Regenerative Technology (Harvard Apparatus Regenerative Technology) Intrinsic Value: Projected FCF : $-4.20 (As of May. 24, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Harvard Apparatus Regenerative Technology Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-24), Harvard Apparatus Regenerative Technology's Intrinsic Value: Projected FCF is $-4.20. The stock price of Harvard Apparatus Regenerative Technology is $2.45. Therefore, Harvard Apparatus Regenerative Technology's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Harvard Apparatus Regenerative Technology's Intrinsic Value: Projected FCF or its related term are showing as below:

HRGN's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.3
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Harvard Apparatus Regenerative Technology Intrinsic Value: Projected FCF Historical Data

The historical data trend for Harvard Apparatus Regenerative Technology's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Apparatus Regenerative Technology Intrinsic Value: Projected FCF Chart

Harvard Apparatus Regenerative Technology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.20 -12.14 -9.25 -8.00 -4.42

Harvard Apparatus Regenerative Technology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.99 -5.39 -5.05 -4.42 -4.20

Competitive Comparison of Harvard Apparatus Regenerative Technology's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Harvard Apparatus Regenerative Technology's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Apparatus Regenerative Technology's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harvard Apparatus Regenerative Technology's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Harvard Apparatus Regenerative Technology's Price-to-Projected-FCF falls into.



Harvard Apparatus Regenerative Technology Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Harvard Apparatus Regenerative Technology's Free Cash Flow(6 year avg) = $-5.38.

Harvard Apparatus Regenerative Technology's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Mar24)*0.8)/Shares Outstanding (Diluted Average)
=(10.918777632373*-5.38272+0.175*0.8)/13.947
=-4.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harvard Apparatus Regenerative Technology  (OTCPK:HRGN) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Harvard Apparatus Regenerative Technology's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=2.45/-4.2039666406629
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harvard Apparatus Regenerative Technology Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Harvard Apparatus Regenerative Technology's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Harvard Apparatus Regenerative Technology (Harvard Apparatus Regenerative Technology) Business Description

Traded in Other Exchanges
N/A
Address
84 October Hill Road, Suite 11, Holliston, MA, USA, 01746
Harvard Apparatus Regenerative Technology Inc is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastrointestinal system and the airway resulting from cancer, trauma, or birth defects. The company's technology is based on its proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs.
Executives
Junli He director C/O NO.1, COUNTRY GARDEN ROAD, BEIJIAO TOWN, SHUNDE DISTRICT, FOSHAN F4 528300
James E. Shmerling director 975 JOHNSON FERRY ROAD, SUITE 450, ATLANTA GA 30342
Dst Capital Llc 10 percent owner C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Ronald J Packard director 2300 CORPORATE PARK DRIVE, HERNDON VA 20171
Jing Chen director C/O BIOSTAGE,INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 02110
Hong Yu officer: President C/O BIOSTAGE, INC. 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Damasio Joseph Luis Jr officer: Chief Financial Officer 14 NORFOLK AVENUE, SOUTH EASTON MA 02375
David Green director, officer: See Remarks C/O HARVARD BIOSCIENCE INC, 84 OCTOBER HILL ROAD, HOLLISTON MA 01746-1371
William Fodor officer: Chief Scientific Officer C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Peter A. Pellegrino officer: Interim VP of Finance C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Herman Sanchez director 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
James Mastridge officer: See Remarks C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746
Jeffrey E Young director 60 WESTVIEW STREET, LEXINGTON MA 02421
Wei Zhang director C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Ting Li director C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746